Who are Metformin and Saxagliptin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Metformin plus vildagliptin, Metformin + Janufer (Janumet).

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/metformin-and-saxagliptin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Metformin and Saxagliptin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Metformin and Saxagliptin (Metformin and Saxagliptin) competitive landscape: 2 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Biguanide + DPP-4 inhibitor combination. Area: Diabetes.

marketed Biguanide + DPP-4 inhibitor combination Metformin: mitochondrial glycerophosphate dehydrogenase; Saxagliptin: DPP-4 (dipeptidyl peptidase-4) Diabetes Small molecule Live · refreshed every 30 min

Target snapshot

Metformin and Saxagliptin (Metformin and Saxagliptin) — ikfe-CRO GmbH. Metformin reduces hepatic glucose production and improves insulin sensitivity, while saxagliptin inhibits DPP-4 to increase incretin-mediated insulin secretion and reduce glucagon.

Comparator set (2 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
Metformin and Saxagliptin TARGET	Metformin and Saxagliptin	ikfe-CRO GmbH	marketed	Biguanide + DPP-4 inhibitor combination	Metformin: mitochondrial glycerophosphate dehydrogenase; Saxagliptin: DPP-4 (dipeptidyl peptidase-4)
Metformin plus vildagliptin	Metformin plus vildagliptin	Sheba Medical Center	marketed	Biguanide + DPP-4 inhibitor combination	Metformin: mitochondrial glycerophosphate dehydrogenase; Vildagliptin: DPP-4 (dipeptidyl peptidase-4)
Metformin + Janufer (Janumet)	Metformin + Janufer (Janumet)	Meir Medical Center	phase 3	Biguanide + DPP-4 inhibitor combination	Metformin: mitochondrial glycerophosphate dehydrogenase; Sitagliptin: DPP-4 enzyme

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Biguanide + DPP-4 inhibitor combination class)

Meir Medical Center · 1 drug in this class
Sheba Medical Center · 1 drug in this class
ikfe-CRO GmbH · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Metformin and Saxagliptin — Competitive Intelligence Brief. https://druglandscape.com/ci/metformin-and-saxagliptin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab